BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 28965273)

  • 21. The impact of surgery on the efficacy of adjuvant therapy in glioblastoma multiforme.
    Brzozowska A; Toruń A; Mazurkiewicz M
    Adv Clin Exp Med; 2015; 24(2):279-87. PubMed ID: 25931361
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of waiting time after surgery and overall time of postoperative radiochemotherapy on treatment outcome in glioblastoma multiforme.
    Seidlitz A; Siepmann T; Löck S; Juratli T; Baumann M; Krause M
    Radiat Oncol; 2015 Aug; 10():172. PubMed ID: 26276734
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of oligodendroglial component in glioblastoma (GBM-O): Is the outcome favourable than glioblastoma?
    Goda JS; Lewis S; Agarwal A; Epari S; Churi S; Padmavati A; Gupta T; Shetty P; Moiyadi A; Jalali R
    Clin Neurol Neurosurg; 2015 Aug; 135():46-53. PubMed ID: 26038275
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma.
    Minniti G; Lanzetta G; Scaringi C; Caporello P; Salvati M; Arcella A; De Sanctis V; Giangaspero F; Enrici RM
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):93-9. PubMed ID: 22079725
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic factors in glioblastoma patients managed with radiotherapy combined with temozolomide.
    Peponi E; Tourkantonis I; Tasiou I; Pavlidis N; Pentheroudakis G; Tsekeris P
    J BUON; 2014; 19(3):718-23. PubMed ID: 25261658
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
    Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of GSTP1 rs1695 polymorphism on survival in male patients' amyotrophic lateral sclerosis: a genetic association study in Brazilian population.
    de Sousa Barros JB; de Faria Santos K; da Cruz Pereira Bento D; Prado Assunção LD; da Silva Santos R; da Silva Reis AA
    Mol Biol Rep; 2022 Feb; 49(2):1655-1659. PubMed ID: 34623592
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A high frequency of MSH6 G268A polymorphism and survival association in glioblastoma.
    Pei C; Chen H; Jia X; Yan L; Zou Y; Jiang C; Jin H; Kang C; Jiang T; Ren H
    Int J Neurosci; 2013 Feb; 123(2):114-20. PubMed ID: 23057844
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognosis factors of survival time in patients with glioblastoma multiforme: a multivariate analysis of 340 patients.
    Mineo JF; Bordron A; Baroncini M; Ramirez C; Maurage CA; Blond S; Dam-Hieu P
    Acta Neurochir (Wien); 2007 Mar; 149(3):245-52; discussion 252-3. PubMed ID: 17273889
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Standard (60 Gy) or short-course (40 Gy) irradiation plus concomitant and adjuvant temozolomide for elderly patients with glioblastoma: a propensity-matched analysis.
    Minniti G; Scaringi C; Lanzetta G; Terrenato I; Esposito V; Arcella A; Pace A; Giangaspero F; Bozzao A; Enrici RM
    Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):109-15. PubMed ID: 25442339
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Contribution of low-molecular weight heparin addition to concomitant chemoradiotherapy in the treatment of glioblastoma multiforme.
    Zincircioglu SB; Kaplan MA; Isikdogan A; Cil T; Karadayi B; Dirier A; Kucukoner M; Inal A; Yildiz I; Aggil F; Donmez O; Urakci Z; Pekkolay Z; Firat U
    J BUON; 2012; 17(1):124-7. PubMed ID: 22517705
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Toxicity and survival in primary glioblastoma patients treated with concomitant plus adjuvant temozolomide versus adjuvant temozolomide: results of a single-institution, retrospective, matched-pair analysis.
    Gutenberg A; Bock HC; Reifenberger G; Brück W; Giese A
    Acta Neurochir (Wien); 2013 Mar; 155(3):429-35. PubMed ID: 23254891
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcome of conventional treatment and prognostic factor in elderly glioblastoma patients.
    Oh SW; Jee TK; Kong DS; Nam DH; Lee JI; Seol HJ
    Acta Neurochir (Wien); 2014 Apr; 156(4):641-51. PubMed ID: 24553726
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outcome of salvage treatment for recurrent glioblastoma.
    Kim HR; Kim KH; Kong DS; Seol HJ; Nam DH; Lim DH; Lee JI
    J Clin Neurosci; 2015 Mar; 22(3):468-73. PubMed ID: 25595963
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacogenetic study in rectal cancer patients treated with preoperative chemoradiotherapy: polymorphisms in thymidylate synthase, epidermal growth factor receptor, GSTP1, and DNA repair genes.
    Páez D; Salazar J; Paré L; Pertriz L; Targarona E; del Rio E; Barnadas A; Marcuello E; Baiget M
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1319-27. PubMed ID: 21570215
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SEL1L SNP rs12435998, a predictor of glioblastoma survival and response to radio-chemotherapy.
    Mellai M; Cattaneo M; Storaci AM; Annovazzi L; Cassoni P; Melcarne A; De Blasio P; Schiffer D; Biunno I
    Oncotarget; 2015 May; 6(14):12452-67. PubMed ID: 25948789
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma.
    Gramatzki D; Kickingereder P; Hentschel B; Felsberg J; Herrlinger U; Schackert G; Tonn JC; Westphal M; Sabel M; Schlegel U; Wick W; Pietsch T; Reifenberger G; Loeffler M; Bendszus M; Weller M
    Neurology; 2017 Apr; 88(15):1422-1430. PubMed ID: 28298550
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of delays in initiating postoperative chemoradiation while determining the MGMT promoter-methylation statuses of patients with primary glioblastoma.
    Adeberg S; Bostel T; Harrabi S; Bernhardt D; Welzel T; Wick W; Debus J; Combs SE
    BMC Cancer; 2015 Jul; 15():558. PubMed ID: 26223282
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
    Li H; Li J; Cheng G; Zhang J; Li X
    Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glioblastoma: clinical characteristics, prognostic factors and survival in 492 patients.
    Stark AM; van de Bergh J; Hedderich J; Mehdorn HM; Nabavi A
    Clin Neurol Neurosurg; 2012 Sep; 114(7):840-5. PubMed ID: 22377333
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.